## Breast Cancer

### Endocrine Therapy
- **ER/PR-POSITIVE HER2 NEGATIVE**
  - No Trial Currently Available
  - IRB#6256-ISPY2 Investigation of Serial Studies to Predict your Therapeutic response with imaging/molecular

### HER2 POSITIVE
- **TRIPLE NEGATIVE**
  - No Trial Currently Available

### Surgical Therapy
- IRB#9340- Phase II breast conservation surgery and radiation therapy study

### Adjuvant Therapy
- No Trial Currently Available

### 1st line MBC Therapy
- IRB#16390 A Phase 1/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients with Advanced Breast Cancer

### 2nd line MBC Therapy
- IRB#1351 Phase 3 Trial of Standard Chemotherapy With or Without a PARP Inhibitor in Metastatic or Locally Advanced
- IRB#16379 C31006: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor

### 3rd line MBC Therapy
- IRB #17016 COMPLEMENT-1: An open-label Phase 3 to evaluate safety and efficacy of ribociclib in combination with Irinotecan
- IRB#15366 Phase 2 Study of ONT-380 vs. Placebo with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (Applies to Adjuvant, 1st line and beyond HER2+ MBC therapy)

### “Heavily Pre-treated” Therapy
- No Trial Currently Available

### Key
- Open for Enrollment
- In Development
- Enrollment on Hold

[http://www.ohsu.edu/research/rda/so/knight.php](http://www.ohsu.edu/research/rda/so/knight.php)